SCHEMBL7988906

SCHEMBL7988906

NC(=NC(=O)c1ccc(N2CCN(C(=O)c3ccco3)CC2)c(C(F)(F)F)c1)NCS(=O)(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 7/20 0.48
MAPT P10636 6/20 0.48
HTT P42858 5/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 3/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
MAPK1 P28482 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137546 0.86 SLC9A1 (0.53) SLC9A1CYP3A4CYP2C19MEN1KMT2A
SCHEMBL6137374 0.85 SLC9A1 (0.73) SLC9A1CYP3A4CYP2C19CA12CA1
SCHEMBL7985443 0.84 SLC9A1 (0.51) SLC9A1CYP3A4CYP2C19
SCHEMBL27522789 0.78 ALDH1A1 (0.51) SLC9A1CYP3A4CYP2C19ALDH1A1MAPT
SCHEMBL6137327 0.78 ALDH1A1 (0.47) SLC9A1CYP3A4CYP2C19ALDH1A1MAPT
SCHEMBL7612077 0.77 MAPT (0.52) SLC9A1CYP3A4CYP2C19ALDH1A1MAPT
SCHEMBL7971257 0.76 ALDH1A1 (0.59) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL2683734 0.73 SLC9A1 (0.66) SLC9A1CYP3A4CYP2C19ALDH1A1MAPT
Sabiporide SCHEMBL27472449 0.71 SLC9A1 (0.89) SLC9A1CYP3A4CYP2C19
SCHEMBL7985442 0.71 SLC9A1 (0.53) SLC9A1CYP3A4CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6323207-B1 TREATMENT OR REDUCTION OF TISSUE DAMAGE DUE TO ISCHAEMIA WHICH COMPRISES ADMINISTERING TO A HOST SUFFERING FROM ISCHAEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-11-27 US disclosed